GLP1R and type 2 diabetes mellitus: The SURPASS-2 trial, for instance, demonstrated that tirzepatide achieved superior glycemic management and greater weight reduction compared to subcutaneous semaglutide, another GLP-1 receptor agonist, in patients with T2DM inadequately managed with metformin alone (4), (5).